CFM
OBIO icon

Catalyst Funds Management’s Orchestra BioMed OBIO Stock Holding History

Catalyst Funds Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$117K Buy
+27,644
New +$118K 0.02% 481
2025
Q3 		– Sell
-11,400
Closed -$30.6K – 602
2025
Q2 		$30.6K Buy
+11,400
New +$33.3K 0.01% 403

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Catalyst Funds Management's OBIO Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 27,644 shares worth $117K. The stake represents 0.02% of the portfolio and ranks #481 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in OBIO as recently as Q2 2025.

Catalyst Funds Management first reported a position in OBIO in Q2 2025 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Catalyst Funds Management held 27,644 shares of Orchestra BioMed worth $117K as of Q1 2026.
  • Orchestra BioMed was a new Catalyst Funds Management position in Q1 2026.
  • Orchestra BioMed made up 0.02% of Catalyst Funds Management's portfolio in Q1 2026, its #481 holding.
  • Catalyst Funds Management first reported a position in Orchestra BioMed in Q2 2025 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.